Glenmark Pharmaceuticals announced that it has entered into a definitive agreement with Dr Reddy’s Laboratories to divest – subject to completion of specific precedent actions and closing activities – it’s brand Momat Rino (for Russia, Kazakhstan, and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along with rights to the trademarks, dossiers, and patents for the territories mentioned.
The divested brand and its extensions represent two types of products, (a) Mometasone mono-product and (b) combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.
Robert Crockart, chief commercial officer, Glenmark Pharmaceuticals, commented, “In line with our strategy to launch Ryaltris, our global anti-allergy brand, in the markets of Russia and other CIS countries, we decided to divest the Momat Rino brand and its extension. As we await approval to launch Ryaltris in the Russian market, we look forward to strengthening our respiratory franchise in the Russia or CIS region. We remain committed to the respiratory space globally.”
Glenmark Pharmaceuticals (GPL) is a global research-led pharmaceutical company with a presence across Generics, Specialty, and OTC business with over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology, and oncology.
